Janssen Announces Phase 1 Results for Bispecific Antibody Amivantamab in the Treatment of Patients with Advanced Non-Small Cell Lung Cancer Harbouring Exon 20 Insertion Mutations
Amivantamab-treated patients achieved durable remissions in CHRYSALIS study; data will be presented during ASCO Virtual Scientific Programme1 BEERSE, Belgium–(BUSINESS WIRE)–The…